Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies

E. Fonsatti, M. Altomonte, S. Coral, C. De Nardo, E. Lamaj, L. Sigalotti, P. G. Natali, Michele Maio

Research output: Contribution to journalArticle

Abstract

Over the past two decades, complement (C)-activating monoclonal antibodies (mAb), directed to specific tumor-associated antigens (TAA), have been extensively utilized for passive immunotherapy of solid tumors of different histology. However, the clinical outcome of this therapeutic approach has been substantially disappointing; antigenic heterogeneity of neoplastic cells and their limited accessibility by therapeutic mAb, have been provided as substantial explanations for the poor clinical results obtained. Nevertheless, in light of the recent advances in the knowledge of the mechanisms regulating C-activity, it begins to be evident that membrane and soluble C-inhibitory proteins play a key role in the protection of neoplastic cells from C-attack, providing additional insights on biological features of transformed cells that may hamper the clinical efficacy of humoral immunotherapy. Among C-regulatory proteins investigated, this review will focus on protectin (CD59) that represents the main restriction factor of C-susceptibility of neoplastic cells from solid malignancies. In view of the functional role of CD59, we will describe its tissue distribution and biological features in malignant neoplasms; major emphasis will be given to cutaneous melanoma, in which the C-regulatory role of CD59 has been extensively investigated, and clinical approaches of humoral immunotherapy have been implemented. According to the available data, the foreseeable strategies to improve the therapeutic efficacy of humoral immunotherapy of solid malignancies will be discussed.

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalClinica Terapeutica
Volume151
Issue number3
Publication statusPublished - May 2000

Fingerprint

CD59 Antigens
Immunotherapy
Protein C
Neoplasms
Monoclonal Antibodies
Passive Immunization
Cytoprotection
Neoplasm Antigens
Tissue Distribution
Melanoma
Histology
Therapeutics
Skin
Membranes

Keywords

  • CD59
  • Complement
  • Immunotherapy
  • Monoclonal antibodies
  • Protectin
  • Solid tumors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fonsatti, E., Altomonte, M., Coral, S., De Nardo, C., Lamaj, E., Sigalotti, L., ... Maio, M. (2000). Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. Clinica Terapeutica, 151(3), 187-193.

Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. / Fonsatti, E.; Altomonte, M.; Coral, S.; De Nardo, C.; Lamaj, E.; Sigalotti, L.; Natali, P. G.; Maio, Michele.

In: Clinica Terapeutica, Vol. 151, No. 3, 05.2000, p. 187-193.

Research output: Contribution to journalArticle

Fonsatti, E, Altomonte, M, Coral, S, De Nardo, C, Lamaj, E, Sigalotti, L, Natali, PG & Maio, M 2000, 'Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies', Clinica Terapeutica, vol. 151, no. 3, pp. 187-193.
Fonsatti E, Altomonte M, Coral S, De Nardo C, Lamaj E, Sigalotti L et al. Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. Clinica Terapeutica. 2000 May;151(3):187-193.
Fonsatti, E. ; Altomonte, M. ; Coral, S. ; De Nardo, C. ; Lamaj, E. ; Sigalotti, L. ; Natali, P. G. ; Maio, Michele. / Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies. In: Clinica Terapeutica. 2000 ; Vol. 151, No. 3. pp. 187-193.
@article{0d316166aa84452182e48e88f7b8ffec,
title = "Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies",
abstract = "Over the past two decades, complement (C)-activating monoclonal antibodies (mAb), directed to specific tumor-associated antigens (TAA), have been extensively utilized for passive immunotherapy of solid tumors of different histology. However, the clinical outcome of this therapeutic approach has been substantially disappointing; antigenic heterogeneity of neoplastic cells and their limited accessibility by therapeutic mAb, have been provided as substantial explanations for the poor clinical results obtained. Nevertheless, in light of the recent advances in the knowledge of the mechanisms regulating C-activity, it begins to be evident that membrane and soluble C-inhibitory proteins play a key role in the protection of neoplastic cells from C-attack, providing additional insights on biological features of transformed cells that may hamper the clinical efficacy of humoral immunotherapy. Among C-regulatory proteins investigated, this review will focus on protectin (CD59) that represents the main restriction factor of C-susceptibility of neoplastic cells from solid malignancies. In view of the functional role of CD59, we will describe its tissue distribution and biological features in malignant neoplasms; major emphasis will be given to cutaneous melanoma, in which the C-regulatory role of CD59 has been extensively investigated, and clinical approaches of humoral immunotherapy have been implemented. According to the available data, the foreseeable strategies to improve the therapeutic efficacy of humoral immunotherapy of solid malignancies will be discussed.",
keywords = "CD59, Complement, Immunotherapy, Monoclonal antibodies, Protectin, Solid tumors",
author = "E. Fonsatti and M. Altomonte and S. Coral and {De Nardo}, C. and E. Lamaj and L. Sigalotti and Natali, {P. G.} and Michele Maio",
year = "2000",
month = "5",
language = "English",
volume = "151",
pages = "187--193",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "3",

}

TY - JOUR

T1 - Emerging role of protectin (CD59) in humoral immunotherapy of solid malignancies

AU - Fonsatti, E.

AU - Altomonte, M.

AU - Coral, S.

AU - De Nardo, C.

AU - Lamaj, E.

AU - Sigalotti, L.

AU - Natali, P. G.

AU - Maio, Michele

PY - 2000/5

Y1 - 2000/5

N2 - Over the past two decades, complement (C)-activating monoclonal antibodies (mAb), directed to specific tumor-associated antigens (TAA), have been extensively utilized for passive immunotherapy of solid tumors of different histology. However, the clinical outcome of this therapeutic approach has been substantially disappointing; antigenic heterogeneity of neoplastic cells and their limited accessibility by therapeutic mAb, have been provided as substantial explanations for the poor clinical results obtained. Nevertheless, in light of the recent advances in the knowledge of the mechanisms regulating C-activity, it begins to be evident that membrane and soluble C-inhibitory proteins play a key role in the protection of neoplastic cells from C-attack, providing additional insights on biological features of transformed cells that may hamper the clinical efficacy of humoral immunotherapy. Among C-regulatory proteins investigated, this review will focus on protectin (CD59) that represents the main restriction factor of C-susceptibility of neoplastic cells from solid malignancies. In view of the functional role of CD59, we will describe its tissue distribution and biological features in malignant neoplasms; major emphasis will be given to cutaneous melanoma, in which the C-regulatory role of CD59 has been extensively investigated, and clinical approaches of humoral immunotherapy have been implemented. According to the available data, the foreseeable strategies to improve the therapeutic efficacy of humoral immunotherapy of solid malignancies will be discussed.

AB - Over the past two decades, complement (C)-activating monoclonal antibodies (mAb), directed to specific tumor-associated antigens (TAA), have been extensively utilized for passive immunotherapy of solid tumors of different histology. However, the clinical outcome of this therapeutic approach has been substantially disappointing; antigenic heterogeneity of neoplastic cells and their limited accessibility by therapeutic mAb, have been provided as substantial explanations for the poor clinical results obtained. Nevertheless, in light of the recent advances in the knowledge of the mechanisms regulating C-activity, it begins to be evident that membrane and soluble C-inhibitory proteins play a key role in the protection of neoplastic cells from C-attack, providing additional insights on biological features of transformed cells that may hamper the clinical efficacy of humoral immunotherapy. Among C-regulatory proteins investigated, this review will focus on protectin (CD59) that represents the main restriction factor of C-susceptibility of neoplastic cells from solid malignancies. In view of the functional role of CD59, we will describe its tissue distribution and biological features in malignant neoplasms; major emphasis will be given to cutaneous melanoma, in which the C-regulatory role of CD59 has been extensively investigated, and clinical approaches of humoral immunotherapy have been implemented. According to the available data, the foreseeable strategies to improve the therapeutic efficacy of humoral immunotherapy of solid malignancies will be discussed.

KW - CD59

KW - Complement

KW - Immunotherapy

KW - Monoclonal antibodies

KW - Protectin

KW - Solid tumors

UR - http://www.scopus.com/inward/record.url?scp=0034182605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034182605&partnerID=8YFLogxK

M3 - Article

C2 - 10958054

AN - SCOPUS:0034182605

VL - 151

SP - 187

EP - 193

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 3

ER -